Smoking cessation and the cardiovascular patient

Current Opinion in Cardiology

Volumn 30, Issue 5, 2015, Pages 506-511

  Prochaska, Judith J ^a   Benowitz, Neal L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cigarette; Nicotine; Quitline; Tobacco

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; VARENICLINE;

CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED PRACTICE; HARM REDUCTION; HUMAN; LONG TERM EXPOSURE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORBIDITY; NICOTINE REPLACEMENT THERAPY; PATIENT SAFETY; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; TELEHEALTH; TOBACCO USE; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; ECONOMICS; EPIDEMIOLOGY; HEALTH PROMOTION; PROCEDURES; PSYCHOLOGY; RISK REDUCTION; THERAPY; TOBACCO;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HEALTHY PEOPLE PROGRAMS; HUMANS; RISK REDUCTION BEHAVIOR; SMOKING; SMOKING CESSATION; TOBACCO; TOBACCO USE CESSATION PRODUCTS;

EID: 84942611614     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000204     Document Type: Review

References (49)

1. Eriksen M, Mackay J, Schluger N, et al. The tobacco atlas. Created by the American Cancer Society and the W orld Lung Foundation. 5th ed. Atlanta, GA: American Cancer Society; 2015. Highly visual compilation of data on the global tobacco epidemic with an interactive website, http://www.tobaccoatlas.org. Covers the health, legal, economic, development, and environmental landscape of global tobacco control.
2. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013; 368:341-350.
3. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-Analysis of cohort studies. Arch Intern Med 2000; 160:939-944. 4.
4. U.S. Department of Health and Human Services: the health consequences of sm oking-50 years of progress: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Fifty-year anniversary comprehensive report on the health consequences of smoking and progress made in tobacco control in the United States. Chapter 8 centers on tobacco and cardiovascular disease. 5.
5. Jamal A, Agaku IT, O'Connor E, et al. Current cigarette smoking among adults: United States, 2005-2013. MMWR Morb Mortal Wkly Rep 2014; 63:1108-1112. Centers for Disease Control epidemiologic report on tobaco use rates am ong adults in the United States.
6. Department of Health and Human Services. PHS: how tobacco causes disease: the biology and behavioral basis for smoking-Attributable disease. A report of the surgeon general. DHHS (CDC). Washington, DC: US Government Printing Office; 2010.
7. Agha G, Loucks EB, Tinker LF, et al. Healthy lifestyle and decreasing risk of heart failure in women: the Women's Health Initiative Observational study. J Am Coll Cardiol 2014; 64:1777-1785.
8. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2003; CD003041.
9. Gerber Y, Rosen LJ, Goldbourt U, et al., Israel Study Group on First Acute Myocardial Infarction. Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol 2009; 54:2382-2387.
10. Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peri pheral artery disease. J Vasc Surg 2014; 60:1565-1571.
11. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
12. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-Analysis. Coc hrane Database Syst Rev 2013; 5:CD009329.
13. Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-Analysis. Circulation 2014; 129:28-41. Network meta-Analysis focused on cardiovascular safety of smoking cessation pharmacotherapies.
14. Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement t herapy (NRT) for smoking cessation. A systematic review and meta-Analysis of one hundred and twenty studies involving 177 390 individuals. Tob Induc Dis 2010; 8:8.
15. Stead LF, Perera R, Bullen C, e t al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11:CD000146.
16. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs 2010; 70:643-650.
17. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessatio n: a randomized clinical trial. JAMA 2014; 312:155-161. One of the first, and adequately powered, randomized controlled trials of combination nicotine replacement and varenicline use for smoking cessation.
18. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone A randomised controlled trial. BMC Med 2013; 11:140.
19. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014; 311:155-163. The first r andomized controlled trial of combination varenicline and bupropion treatment.
20. Hong AS, Elrashidi MY, Schroeder DR, Ebbert JO. Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J Subst Abuse Treat 2015; 52:78-81.
21. Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015; 175:504-511. Randomized controlled trial examining extended (24-week) and maintenance (52-week) nicotine patch treatment relative to a standard 8-week course.
22. Tonstad S,Tonnesen P,Hajek P,et al. V arenicline Phase 3 Study G: effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 2006 296, 64-71.
23. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145-154. Randomized controlled trial evaluating maintenance use of varenicl ine in smokers with schizophrenia or bipolar disorder.
24. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135:423-433.
25. Cox LS, Patten CA, Niaura RS, et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004; 19:828-834.
26. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking ces sation through smoking reduction: a randomized clinical trial. JAMA 2015; 313:687-694. Randomized controlled trial testing the use of varenicline as a reduce-to-quit smoking cessation strategy with smokers not initially ready to quit .
27. Dempsey D, Tutka P, Jacob P 3rd, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004; 76:64-72.
28. Le rman C, Schnoll RA, Hawk LW Jr., et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2015; 3:131-138. Prospective randomized controlled trial testing the NMR as a biomarker of response to smoking cessation medications.
29. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-Analysis. Thorax 2013; 68:1037-1042.
30. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4:CD006103.
31. Geneva S. World Health Organization: WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship. 2011; http://www.who.int/tobacco/surveillance/policy/country-profile/en/. [Accessed 22 May 2015] 32.
32. Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med 2014; 371:2353-2362. Open-label randomized comparative effectiveness trial of cytisine compared with nicotine patch conducted in New Zealand.
33. Arefalk G, Hambraeus K, Lind L, et al. Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. Circulation 2014; 130:325-332. Analys is of continued snus use and mortality risk among patients postmyocardial infarction.
34. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-Analysis. BMJ 2009; 339:b3060.
35. Hansson J, Galanti MR, Hergens MP, et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 2012; 27:771-779.
36. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23:133-139. Analysis of 12 fir st-generation (cigarette-like) brand ENDS for levels of toxic compounds in the aerosol across brands and relative to cigarette smoke.
37. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation 2014; 129:1972-1986. Comprehensive review of e-cigarette use and safety studies to date.
38. Caponnetto P, Campagna D, Cibella F, et al. Efficiency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013; 8:e66317.
39. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382:1629-1637.
40. Brose LS, Hitchman SC, Brown J, et al. Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, c essation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction 2015. [Epub ahead of print] Observational study of e-cigarette users and quit attempts over 1-year follow-up.
41. Schauer GL, Malarcher AM, Zhang L, et al. Prevalence and correlates of quitline awareness and utilization in the United States: an update from the 2009-2010 National Adult Tobacco Survey. Nicotine Tob Res 2013; 2013:1-10.
42. B erndt N, Bolman C, Lechner L, et al. Economic evaluation of a telephoneand face-to-face-delivered counseling intervention for smoking cessation in patients with coronary heart disease. Eur J Health Econ 2015. [Epub ahead of prin t] Analysis of quitline versus in-person cessation counseling specifically among cardiac patients.
43. Huang K, Liu W, He D, et al. Telehealth interventions versus center-based cardiac rehabilitation of coronary artery disease: a systematic review and meta-Analysis. Eur J Prev Cardiol 2014. [Epub ahead of print] Comparison of the effect of telehealth versus in-person cardiac rehabilitation on smoking outcomes.
44. Stead LF, Hartmann-B oyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013; 8:CD002850.
45. Cahill K, Perera R. Competitions and incentives for smoking cessation. Cochrane Database Syst Rev 2011; CD004307.
46. Volpp KG, Troxel AB, PaulyMV, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360:699-709.
47. Volpp KG, Asch DA, Galvin R, Loewenstein G. Redesigning employee health incentives: lessons from behavioral economics. N Engl J Med 2011; 365:388-390.
48. Halpern SD, Fren ch B, Small DS, et al. Randomized trial of four financialincentive programs for smoking cessation. N Engl J Med 2015; 372:2108-2117. Comparison of reward versus deposit-based incentives programs for smoking cessation on sh ort and long-term outcomes.
49. Hamilton FL, Laverty AA, Huckvale K, et al. Financial incentives and inequalities in smoking cessation interventions in primary care: before-And-After study. Nicotine Tob Res 2015 . [Epub ahead of print]